

Title (en)

METHODS OF ADMINISTERING COMPOSITIONS COMPRISING DOCOSAPENTAENOIC ACID

Title (de)

VERFAHREN ZUR VERABREICHUNG VON ZUSAMMENSETZUNGEN MIT DOCOSAPENTAENSÄURE

Title (fr)

PROCÉDÉS D'ADMINISTRATION DE COMPOSITIONS COMPRENANT DE L'ACIDE DOCOSAPENTAÉNOÏQUE

Publication

EP 2928462 A2 20151014 (EN)

Application

EP 13861305 A 20131206

Priority

- US 201261734331 P 20121206
- US 201361780948 P 20130313
- US 2013073714 W 20131206

Abstract (en)

[origin: WO2014089501A1] Orally administrable composition comprising fatty acids, wherein at least 50% by weight of the fatty acids comprise omega-3-fatty acids, salts or derivatives thereof, wherein the omega-3 fatty acids comprise eicosapentaenoic acid (EPA; C20:5-n3), docosapentaenoic acid (DPA; C22:5-n3), and docosahexaenoic acid (DHA; C22:6-n3), wherein the ratio of DHA to EPA (DHA:EPA) is less than 1:20, and wherein the ratio of DHA to DPA (DHA:DPA) is less than 2:1 are provided. These compositions can be used for the treatment or prophylaxis of dyslipidemic, cardiovascular, CNS, inflammatory, and other diseases/conditions or risk factors therefore.

IPC 8 full level

A61K 31/225 (2006.01); **A23D 9/00** (2006.01); **A23D 9/06** (2006.01); **A61K 9/48** (2006.01); **A61K 31/202** (2006.01); **A61K 31/40** (2006.01); **C11B 5/00** (2006.01)

CPC (source: CN EP KR)

A23D 9/00 (2013.01 - EP); **A23D 9/06** (2013.01 - EP KR); **A61K 9/4825** (2013.01 - EP); **A61K 9/4858** (2013.01 - EP); **A61K 9/4875** (2013.01 - EP); **A61K 31/202** (2013.01 - CN EP KR); **A61K 31/40** (2013.01 - CN); **A61P 3/06** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **C11B 5/0007** (2013.01 - EP KR); **A61K 47/22** (2013.01 - EP)

C-Set (source: CN EP)

CN

1. **A61K 31/202 + A61K 2300/00**

2. **A61K 31/40 + A61K 2300/00**

EP

A61K 31/202 + A61K 2300/00

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

WO 2014089501 A1 20140612; AU 2013354969 A1 20150611; AU 2013354979 A1 20150611; AU 2017232203 A1 20171012; AU 2018229440 A1 20181004; AU 2019216634 A1 20190905; AU 2020203658 A1 20200625; AU 2021201865 A1 20210422; CA 2894183 A1 20140612; CA 2894366 A1 20140612; CN 104902888 A 20150909; CN 104937103 A 20150923; CN 112107570 A 20201222; CN 113274378 A 20210820; EP 2928462 A2 20151014; EP 2928462 A4 20160601; EP 2929041 A1 20151014; EP 2929041 A4 20160608; EP 3888646 A1 20211006; IN 1505MU2015 A 20160527; IN 5009DE2015 A 20151218; JP 2016501248 A 20160118; JP 2016501249 A 20160118; JP 2019172697 A 20191010; JP 2021120407 A 20210819; JP 6881893 B2 20210602; KR 20150103009 A 20150909; KR 20150103671 A 20150911; KR 20210059779 A 20210525; MX 2015007082 A 20160112; MX 2015007085 A 20160112; WO 2014089511 A2 20140612; WO 2014089511 A3 20140731

DOCDB simple family (application)

US 2013073701 W 20131206; AU 2013354969 A 20131206; AU 2013354979 A 20131206; AU 2017232203 A 20170922; AU 2018229440 A 20180912; AU 2019216634 A 20190814; AU 2020203658 A 20200603; AU 2021201865 A 20210324; CA 2894183 A 20131206; CA 2894366 A 20131206; CN 201380063980 A 20131206; CN 201380064003 A 20131206; CN 202010984870 A 20131206; CN 202110585483 A 20131206; EP 13861305 A 20131206; EP 13861394 A 20131206; EP 21170003 A 20131206; IN 1505MU2015 A 20150610; IN 5009DE2015 A 20150610; JP 2015545894 A 20131206; JP 2015545896 A 20131206; JP 2019114492 A 20190620; JP 2021084578 A 20210519; KR 20157016331 A 20131206; KR 20157017202 A 20131206; KR 20217013255 A 20131206; MX 2015007082 A 20131206; MX 2015007085 A 20131206; US 2013073714 W 20131206